Collaborate 2 Cure
December 15, 2016

The Role of Complex Gut Microbiota in the Susceptibility to Colorectal Cancer


Our laboratory uses rat and mouse models of familial colon cancer to study the role of genetic and environmental factors that influence the risk in developing early cancer. Through the use of complex microbiota targeted rederivation in both mouse and rat we have shown that specific bacteria are strongly influencing early adenoma development. Our long term goal is to understand the mechanism of cancer development and the possible protective effect of certain bacteria. I will discuss the possible mechanisms and resources available in my lab and here at MU.

James M. Amos-Landgraf, PhD

Jim received his undergraduate degree from Washington University after which he worked at the Genome center under Eric Green (now director of NHGRI) on the early stages of the Human Genome Project. He moved to Case Western Reserve University and received his doctoral degree in human genetics under Hunting Willard (National Academy member and now director of Marine Biological Lab at Woods Hole). He studied the genetic control of the epigenetic process of X inactivation in female cells. He then moved to the University of Wisconsin and did his postdoctoral work with William Dove (National Academy member) at the McArdle Laboratory for Cancer Research. He was an American Cancer Society Fellow at Wisconsin and developed a rat model of human colon cancer. He joined the University of Missouri faculty in 2012 in Veterinary Pathobiology and is associated with the NIH funded Mouse and Rat resource and research centers. His current research is focusing on the role of the microbiome in colon cancer risk.

Tolerance Induction for Organ Transplants by Myeloid Progenitor Cells


State of the art techniques result in 10-year solid organ graft loss of 50 to over 70% in cardiopulmonary organ transplantation. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a recipient accepts a transplant without immunosuppression, while retaining the ability to fight infections, would reduce graft loss and transplant related complications. The only identified method of inducing robust tolerance involves is bone marrow transplantation (BMT), but clinical translation has been limited due to the associated complications. Other avenues include cell therapy using immunomodulating mature cells such as regulatory T cells. While promising, this approach may be limited in its ability to prevent rejection responses. We propose that progenitor cell therapy, specifically using Myeloid Progenitor cells (MP) may be the best compromise in introducing multiple immunomodulatory cell types without all the complications associated with BMT. Our data to date clearly support this hypothesis. Our ongoing focus is both on better understanding the mechanisms involved, as well as fine-tune the preclinical protocols with eventual clinical use in mind.

Jos Domen, PhD

Jos Domen is a member of the Section of Cardiac Surgery and an Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine. He manages the Cardiac Transplant Research Laboratory at Children’s Mercy Hospital. He earned his PhD at the Netherlands Cancer Institute/University of Amsterdam in Amsterdam, The Netherlands. He completed a post-doctoral fellowship in the Laboratory of Dr Irving Weissman, Dept of Pathology, Stanford University School of Medicine. He has held faculty positions at Duke University, University of Arizona and the Medical College of Wisconsin. In addition he has been a staff scientist at Cellerant Therapeutics in San Carlos, California. Dr Domen joined Children’s Mercy Hospital in February 2011. His research interest includes hematopoietic stem cell and progenitor biology and is currently focused on the use of hematopoietic cell transplantation for tolerance induction, focusing on the role of myeloid progenitor cells in this process.

Location : Kauffman Foundation Conference Center

Paseo Room
4801 Rockhill Rd, Kansas City, MO 64110

Or join virtually via “Zoom”